Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Tomkinson

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology in Drug Development|February 9, 2017
Effect of Sustained Elevated Gastric pH Levels on Gefitinib ExposureWeifeng Tang, Helen Tomkinson, Eric Masson
Journal of Clinical Pharmacology|December 12, 2018
Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in OncologyMark Farha, Eric Masson, Helen Tomkinson, et al.
BMC Clinical Pharmacology|March 19, 2011
Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studiesHelen Tomkinson, John Kemp, Stuart Oliver, et al.
Clinical and Translational Science|March 13, 2024
In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell linesLinda Wanika, Neil D Evans, Martin Johnson, et al.
Journal of Personalized Medicine|December 24, 2021
Imputing Biomarker Status from RWE Datasets-A Comparative StudyCarlos Traynor, Tarjinder Sahota, Helen Tomkinson, et al.
Journal of Clinical Pharmacology|August 14, 2018
Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung CancerXiao Tong, Hongmei Xu, David J Carlile, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 15, 2011
The metabolism of [14C]-zibotentan (ZD4054) in rat, dog and human, the loss of the radiolabel and the identification of an anomalous peak, derived from the animal feedEva M Lenz, Alison Kenyon, Scott Martin, et al.
Clinical Pharmacology and Therapeutics|October 25, 2017
Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of DrugsEmily Schwenger, Venkatesh Pilla Reddy, Ganesh Moorthy, et al.
Molecular Cancer Therapeutics|March 8, 2023
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer ModelRhys D O Jones, Klas Petersson, Areya Tabatabai, et al.
Clinical Therapeutics|October 8, 2017
Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male SubjectsHelen Tomkinson, Eileen McBride, Paul Martin, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology in Drug Development|February 9, 2017
Effect of Sustained Elevated Gastric pH Levels on Gefitinib ExposureWeifeng Tang, Helen Tomkinson, Eric Masson
Journal of Clinical Pharmacology|December 12, 2018
Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in OncologyMark Farha, Eric Masson, Helen Tomkinson, et al.
BMC Clinical Pharmacology|March 19, 2011
Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studiesHelen Tomkinson, John Kemp, Stuart Oliver, et al.
Clinical and Translational Science|March 13, 2024
In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell linesLinda Wanika, Neil D Evans, Martin Johnson, et al.
Journal of Personalized Medicine|December 24, 2021
Imputing Biomarker Status from RWE Datasets-A Comparative StudyCarlos Traynor, Tarjinder Sahota, Helen Tomkinson, et al.
Journal of Clinical Pharmacology|August 14, 2018
Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung CancerXiao Tong, Hongmei Xu, David J Carlile, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 15, 2011
The metabolism of [14C]-zibotentan (ZD4054) in rat, dog and human, the loss of the radiolabel and the identification of an anomalous peak, derived from the animal feedEva M Lenz, Alison Kenyon, Scott Martin, et al.
Clinical Pharmacology and Therapeutics|October 25, 2017
Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of DrugsEmily Schwenger, Venkatesh Pilla Reddy, Ganesh Moorthy, et al.
Molecular Cancer Therapeutics|March 8, 2023
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer ModelRhys D O Jones, Klas Petersson, Areya Tabatabai, et al.
Clinical Therapeutics|October 8, 2017
Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male SubjectsHelen Tomkinson, Eileen McBride, Paul Martin, et al.
Pageof 3